Abstract 568P
Background
Osimertinib (osi), a third-generation, CNS-active EGFR-TKI, is the preferred 1L treatment for EGFRm advanced NSCLC, based on significant clinical benefit in the FLAURA study; however, most patients (pts) will develop disease progression. FLAURA2 (NCT04035486) is a global, phase III, open-label, randomised study of 1L osi + platinum-pemetrexed (pem) vs osi monotherapy in EGFRm advanced NSCLC. The FLAURA2 SRI phase assessed the safety/tolerability of the combination prior to the randomised period. We report final data following 3-years additional follow-up (previous data cut-off [DCO]: 19 Feb 2020).
Methods
Overall, 30 pts (≥18 years; ≥20 years Japan) with locally advanced/metastatic NSCLC received oral osi 80 mg once daily (QD) + either intravenous cisplatin 75 mg/m2 or carboplatin AUC5 + pem 500 mg/m2 every 3 weeks (Q3W) for 4 cycles, then maintenance osi (80 mg QD) + pem 500 mg/m2 (Q3W) until progression/discontinuation. SRI primary endpoint: safety; secondary endpoints: ORR, DCR, duration/depth of response and OS. DCO: 03 Apr 2023.
Results
Median age (range): 61 (45–84) years; 63% female; 73% Asian, 37% former smoker. Median exposure (range): 38.6 (1.9–44.6) months osi / 15.0 (1.0–64.0) cycles pem; 47% ongoing osi and 17% ongoing pem at DCO; 80% completed 4 cycles carbo/cis-platin. With 3 further years’ exposure, 2 more pts had adverse events (AEs) (n=29 [97%] total), 5 more had serious AEs (n=11 [37%] total), 4 more had Grade ≥3 AEs (n=15 [50%] total) and 1 new AE leading to death (n=2 [7%] total). No new cases of ILD/pneumonitis reported. New Grade ≥3 AEs included COVID-19/pneumonia (n=1 each). New AEs leading to discontinuation: 4 pem (n=10 [33%] total); none osi. No new safety signals were observed. Clinical benefit was observed (Table).
Conclusions
Osi + platinum-pem was well tolerated and clinical benefit continued with 3 further years’ exposure. Data support long-term tolerability of 1L osi + platinum-pem for EGFRm advanced NSCLC. Table: 568P
Efficacy endpoint | Osimertinib + carboplatin/cisplatin + pemetrexed (N=30) |
Confirmed ORR, n (%) (95% CI)Complete responsePartial response | 26 (87) (69.3–96.2)3 (10)23 (77) |
Non-response, n (%)Stable disease ≥35 days | 4 (13) |
Median duration of response, months (range) | 34.0 (2.0–43.0) |
Best percentage change from baseline in target lesion size, median % (range) | -59.6 (-100.0 – -6.4) |
DCR, n (%) (95% CI) | 30 (100) (88.4–100.0) |
Median OS, months (95% CI)2 year OS, % (95% CI)3 year OS, % (95% CI) | NR (34.0–NC)90 (72.1–96.7)69 (48.9–82.6) |
Median PFS, months (95% CI)2 year PFS, % (95% CI)3 year PFS, % (95% CI) | NR (25.6–NC)76 (55.9–87.7)55 (35.6–71.0) |
CI, confidence interval; NC, not calculable; NR, not reached
Clinical trial identification
NCT04035486.
Editorial acknowledgement
The authors would like to acknowledge Gemma White, MSc, of Ashfield MedComms, an Inizio Company, for medical writing support in accordance with Good Publications Practice (GPP) guidelines (https://www.ismpp.org/gpp-2022).
Legal entity responsible for the study
AstraZeneca.
Funding
AstraZeneca.
Disclosure
D. Planchard: Financial Interests, Personal, Advisory Board: AstraZeneca, AbbVie, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Merck, Novartis, Janssen, Pfizer, Roche, Pierre-fabre, Takeda, ArriVent, Mirati, Seagen; Non-Financial Interests, Institutional, Coordinating PI: AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Pfizer, Roche, Medimmune, Sanofi-Aventis, Taiho Pharma, Novocure, Daiichi Sankyo, AbbVie, Janssen, Pierre Fabre, Takeda, ArriVent, Mirati, Seagen; Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, AbbVie, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Daiichi Sankyo, Eli Lilly, Merck, Novartis, Janssen, Pfizer, Roche, Pierre Fabre, Takeda, ArriVent, Mirati, Seagen. S. Kim: Non-Financial Interests, Personal, Advisory Role: Amgen, AstraZeneca, Boehringer Ingelheim, Janssen, Norvasc, Takeda, Terrapex, Yuhan; Non-Financial Interests, Personal, Funding: Yuhan; Non-Financial Interests, Personal, Invited Speaker: Boehringer Ingelheim. T.M. Kim: Non-Financial Interests, Personal, Advisory Board: Boryung, Janssen, Novartis, Takeda, Regeneron; Financial Interests, Personal, Advisory Role: AstraZeneca, Boryung, Hanmi, IMBDx, Janssen, Novartis, Takeda, Sanofi, Regeneron, Roche/Genentech, Samsung Bioepis; Non-Financial Interests, Personal, Coordinating PI: Regeneron; Financial Interests, Institutional, Local PI: ABBVIE, AstraZeneca, Bayer, Black Diamond Therapeutics, Blueprint Medicines, Boryung, Bristol Myers Squibb, Celgene, F. Hoffmann-La Roche Ltd/Genentech, Inc, Hanmi, Janssen, Novartis, Regeneron, Sanofi, Takeda, and Yuhan. N. Yanagitani: Non-Financial Interests, Personal, Advisory Board: Pfizer Inc.; Non-Financial Interests, Personal, Speaker, Consultant, Advisor, Consultant: Chugai; Financial Interests, Personal, Speaker, Consultant, Advisor, Lecture Fees: Taiho, MSD, Ono, Bristol Myers Squibb, Novartis, Pfizer Inc., Chugai co., Eli Lilly and Company, Boehringer Ingelheim, Bayer AG. H. Kagamu: Financial Interests, Personal, Research Funding, Collaborative Research Fund: Boehringer Ingelheim Inc., Chugai pharm. Inc., Ono pharm. Inc.; Financial Interests, Personal, Speaker, Consultant, Advisor, Honoraria: AstraZeneca, Bristol Myers Squibb, Ono pharm., Chugai pharm. P. Feng: Non-Financial Interests, Personal, Invited Speaker: Roche, MSD, Ono, AZ; Financial Interests, Personal, Speaker, Consultant, Advisor: PharmaEssentia. B. Hughes: Financial Interests, Personal, Advisory Board: MSD, BMS, AstraZeneca, Roche, Pfizer, Takeda, Sanofi, Eisai; Financial Interests, Personal, Research Funding: Amgen. J.C. Yang: Financial Interests, Institutional, Advisory Board, My institute received fee for my role as advisory board: AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Merck KGaA, Merck Sharp & Dohme, Novartis, Pfizer, Roache/Genentech, Takeda, Yuhan Pharmaceuticals, Janssen, Puma Technology, Gilead, GSK, Dizal Pharmaceutica; Financial Interests, Personal, Coordinating PI: AstraZeneca, MSD, Dizal Pharmaceutical; Non-Financial Interests, Personal, Member: ASCO, ESMO, IASLC; Financial Interests, Personal, Research Funding: AstraZeneca, Roche; Financial Interests, Personal, Steering Committee Member: AstraZeneca, Daiichi Sankyo, Eli Lilly, Merck Sharp & Dohme, Takeda, Yuhan Pharmaceuticals, Janssen, Dizal Pharmaceutical. C.K. Lee: Financial Interests, Personal, Advisory Board: AstraZeneca, Amgen, Takeda, Pfizer, Novartis, GSK, Merck KGA, Roche, Janssen, and MSD; Financial Interests, Personal, Research Grant: AstraZeneca, Amgen, Roche, Merck KGA. P. Mitchell: Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, BMS, Roche, MSD, Novartis, Pfizer ; Financial Interests, Personal, Advisory Role: Grey Wolf; Financial Interests, Personal, Coordinating PI: AstraZeneca, Amgen. Y. Tambo: Financial Interests, Personal, Speaker, Consultant, Advisor: Chugai, AstraZeneca, Taiho, MSD, Pfizer, Kyowa Kirin. E. Armenteros Monterroso: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca. A. Todd: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca. A. Sahasrabudhe: Financial Interests, Personal, Full or part-time Employment: AstraZeneca. P.A. Jänne: Financial Interests, Personal, Advisory Board, Consulting fees for advice on drug development: AstraZeneca, Mirati Therapeutics, Boehringer Ingelheim, Pfizer, Roche/Genentech, Chugai Pharmaceuticals, Eli Lilly and Company, Ignyta, Takeda Oncology, Novartis, Voronoi, SFJ Pharmaceuticals, Biocartis, LOXO Oncology, PUMA, Sanofi, Transcenta, Daiichi Sa; Financial Interests, Personal, Other, Dr. Jänne is a co-inventor on a DFCI owned patent on EGFR mutations licensed to Lab Corp: Lab Corp; Financial Interests, Personal, Research Grant: AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Takeda Oncology, PUMA, Astellas Pharmaceuticals, Daiichi Sankyo; Financial Interests, Personal, Advisory Board, Post marketing royalties from DFCI owned intellectual property on EGFR mutations licensed to Lab Corp: Lab Corp. K. Kobayashi: Financial Interests, Personal, Financially compensated role, Board Chairman: NPO North East Japan Study Group; Financial Interests, Personal, Speaker’s Bureau, Speaker Fees: AstraZeneca, Takeda Pharmaceutical Co., Daiichi Sanko Pharmaceutical Co., Boehringer Ingelheim. All other authors have declared no conflicts of interest.
Resources from the same session
425P - Engineered <italic>Lactococcus lactis</italic> as a personalized cancer vaccine platform induces antitumour immunity via membrane-inserted peptide for neoantigens
Presenter: Meng Zhu
Session: Poster Display
Resources:
Abstract
426P - Characterization of a novel comprehensive genomic profiling test with better detection of heterozygous deletions and gene fusions
Presenter: ryouta kakuta
Session: Poster Display
Resources:
Abstract
427P - Real-world performance of a comprehensive next-generation sequencing (NGS) panel for patients (pts) with solid tumors from Asia and the Middle East (AME)
Presenter: Nitesh Rohatgi
Session: Poster Display
Resources:
Abstract
428P - What do women want to see in a personalized breast cancer risk report? A qualitative study of Asian women of two countries
Presenter: Faustina Audrey Agatha
Session: Poster Display
Resources:
Abstract
429P - Clinical utility and outcomes of liquid biopsy-based next generation sequencing in identification of actionable genomic mutations in solid malignancy: A single center retrospective study in the Philippines
Presenter: Omar Maaño
Session: Poster Display
Resources:
Abstract
436P - Chemotherapy-induced hand-foot syndrome, comparative efficacy and safety of pharmacological prophylaxis: Systematic review and network meta-analysis
Presenter: Anand Srinivasan
Session: Poster Display
Resources:
Abstract
437P - A randomized single blinded phase II trial comparing efficacy and quality of life of topical aloe vera gel plus urea cream versus urea cream alone for prevention of hand-foot syndrome in cancer patients receiving capecitabine
Presenter: Lucksika Wanichtanom
Session: Poster Display
Resources:
Abstract
438P - A novel treatment for immune checkpoint inhibitor-related myocarditis
Presenter: Takahiro Niimura
Session: Poster Display
Resources:
Abstract
439P - Randomized controlled trial evaluating efficacy of topical urea-based cream for capecitabine-associated hand-foot syndrome prevention
Presenter: Concord Wongkraisri
Session: Poster Display
Resources:
Abstract
440P - Real-world adverse events of targeted therapy reported by pharmacist in oncology clinic
Presenter: TIKUMPORN PORNWISETSIRIKUL
Session: Poster Display
Resources:
Abstract